Compare Abeona Therapeutics Inc (ABEO) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Clear Secure Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Clear Secure Inc trades at $54.81 (market cap $5.63B). The key difference: Clear Secure Inc is far larger — about 15.1× Abeona Therapeutics Inc's market cap, and Clear Secure Inc pays a 1.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | YOU | |
|---|---|---|
Market Cap | $373.32M | $5.63B |
Sector | Health | Technology |
52-Week High | $7.23 | $62.36 |
52-Week Low | $4.17 | $28.38 |
Enterprise Value | $228.22M | $4.94B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Clear Secure (YOU) trades at $56.74, up 5.48% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated at P/E 45.39. Recent Q1 2026 earnings beat expectations, and the AWS partnership expansion signals growth potential. Analyst sentiment is mixed with 44% buy ratings and consensus target near current price.
Outlook remains positive given strong member growth and cash flow generation, but high valuation multiples and competitive pressures present risks. The stock's technical overbought condition near resistance at $58 suggests potential near-term consolidation before further upside. Institutional interest appears balanced with moderate net cash flow growth supporting expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
